Clinical Trial Update: Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of Dengue Tetravalent Vaccine (TDV) and recombinant 9-valent HPV vaccine (9vHPV) in participants aged 9 to le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• Dengue Tetravalent Vaccine (TDV) (Dengue tetravalent vaccine)
• recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) (HPV vaccine)

Snippet

Sponsor: Takeda | Conditions: Dengue Fever | Phase 3 | Status: COMPLETED | Results posted: 2024-02-07